Hermes Pharma GmbH
3
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 3 trials
0%
0 trials in Phase 3/4
0%
1 of 0 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (3)
Evaluation of bioequivalence of two products containing 400 mg ibuprofen and 100 mg caffeine: Ibuprofen / Caffeine 400 mg / 100 mg coated granules (Test) vs. Thomapyrin TENSION DUO, 400mg / 100mg Filmtabletten (Reference). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Role: co_sponsor
An open label, randomized, four-period, four-sequence single dose, crossover trial in healthy volunteers to determine the relative bioavailability of Dimenhydrinate 50 mg (Test) administered with and without water vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Reference 1) and Biodramina 50 mg Comprimidos (Reference 2)
Role: co_sponsor
Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einnehmen im Beutel (Comparator). A monocentric, open, randomized, single dose, two-period, crossover trial in healthy volunteers
Role: co_sponsor
All 3 trials loaded